PMID- 26482935
OWN - NLM
STAT- MEDLINE
DCOM- 20160815
LR  - 20181113
IS  - 1420-908X (Electronic)
IS  - 1023-3830 (Linking)
VI  - 64
IP  - 12
DP  - 2015 Dec
TI  - Anti-inflammatory effects of vicenin-2 and scolymoside in vitro and in vivo.
PG  - 1005-21
AB  - AIM AND OBJECTIVE: Two structurally related flavonoids found in Cyclopia 
      subternata, namely vicenin-2 and scolymoside, were examined for its effects on 
      inflammatory responses by monitoring the effects of vicenin-2 and scolymoside on 
      lipopolysaccharide (LPS)-mediated vascular inflammatory responses. METHODS: The 
      anti-inflammatory activities of vicenin-2 and scolymoside were determined by 
      measuring permeability,monocytes adhesion and migration, and activation of 
      pro-inflammatory proteins in LPS-activated HUVECs and mice. RESULTS: We found 
      that post-treatment of each compound inhibited LPS-induced barrier disruption, 
      expression of cell adhesion molecules (CAMs), and adhesion/transendothelial 
      migration of human neutrophils to human endothelial cells. Each compound induced 
      potent inhibition of phorbol-12-myristate 13-acetate (PMA) and LPS-induced 
      endothelial cell protein C receptor (EPCR)shedding. It also suppressed 
      LPS-induced hyperpermeability and leukocytes migration in vivo. Furthermore,each 
      compound suppressed the production of tumor necrosis factor-alpha (TNF-alpha) or 
      Interleukin (IL)-6 and the activation of nuclear factor-kappaB (NF-kappaB) or 
      extracellular regulated kinases (ERK) 1/2 by LPS. Moreover, posttreatment with 
      each compound resulted in reduced LPS-induced lethal endotoxemia. CONCLUSION: 
      Vicenin-2 and scolymoside possess anti-inflammatory functions by inhibiting 
      hyperpermeability,expression of CAMs, and adhesion and migration of leukocytes, 
      thereby endorsing its usefulness as a therapy for vascular inflammatory diseases.
FAU - Kang, Hyejin
AU  - Kang H
FAU - Ku, Sae-Kwang
AU  - Ku SK
FAU - Jung, Byeongjin
AU  - Jung B
FAU - Bae, Jong-Sup
AU  - Bae JS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Inflamm Res
JT  - Inflammation research : official journal of the European Histamine Research 
      Society ... [et al.]
JID - 9508160
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Glucosides)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (apigenin-6,8-di-C-glycopyranoside)
RN  - 0 (interleukin-6, mouse)
RN  - 0 (scolymoside)
RN  - 7V515PI7F6 (Apigenin)
RN  - EC 3.4.24.- (ADAM Proteins)
RN  - EC 3.4.24.86 (ADAM17 Protein)
RN  - KUX1ZNC9J2 (Luteolin)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
SB  - IM
MH  - ADAM Proteins/biosynthesis/genetics
MH  - ADAM17 Protein
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Apigenin/*pharmacology
MH  - Cell Adhesion/drug effects
MH  - Cell Membrane Permeability/drug effects
MH  - Cell Movement/drug effects
MH  - Glucosides/*pharmacology
MH  - Human Umbilical Vein Endothelial Cells/drug effects
MH  - Humans
MH  - Interleukin-6/biosynthesis
MH  - Lipopolysaccharides/antagonists & inhibitors/pharmacology
MH  - Luteolin/*pharmacology
MH  - Macrophage Activation/drug effects
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Monocytes/drug effects
MH  - Tetradecanoylphorbol Acetate/antagonists & inhibitors
EDAT- 2015/10/21 06:00
MHDA- 2016/08/16 06:00
CRDT- 2015/10/21 06:00
PHST- 2015/04/24 00:00 [received]
PHST- 2015/10/06 00:00 [accepted]
PHST- 2015/09/28 00:00 [revised]
PHST- 2015/10/21 06:00 [entrez]
PHST- 2015/10/21 06:00 [pubmed]
PHST- 2016/08/16 06:00 [medline]
AID - 10.1007/s00011-015-0886-x [pii]
AID - 10.1007/s00011-015-0886-x [doi]
PST - ppublish
SO  - Inflamm Res. 2015 Dec;64(12):1005-21. doi: 10.1007/s00011-015-0886-x.